CO2022009085A2 - Derivados espiránicos sustituidos de cadena lineal - Google Patents

Derivados espiránicos sustituidos de cadena lineal

Info

Publication number
CO2022009085A2
CO2022009085A2 CONC2022/0009085A CO2022009085A CO2022009085A2 CO 2022009085 A2 CO2022009085 A2 CO 2022009085A2 CO 2022009085 A CO2022009085 A CO 2022009085A CO 2022009085 A2 CO2022009085 A2 CO 2022009085A2
Authority
CO
Colombia
Prior art keywords
derivatives
straight chain
chain substituted
substituted spiral
spiral
Prior art date
Application number
CONC2022/0009085A
Other languages
English (en)
Inventor
Yanping Xu
Wei Cai
Edward Cleator
Xuedong Dai
Nicolas Freddy J Darville
Xiangjun Deng
Lichao Fang
Liqiang Fu
Ming Li
Kangying Li
Yingtao Liu
Lianzhu Liu
William Marc Maton
Alicia Tee Fuay Ng
Vineet Pande
Olivier Alexis Georges Querolle
Johannes Wilhelmus John F Thuring
Gregor Thomas Urbanietz
Qiwu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2022009085A2 publication Critical patent/CO2022009085A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
CONC2022/0009085A 2019-12-19 2022-06-29 Derivados espiránicos sustituidos de cadena lineal CO2022009085A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04
PCT/CN2020/137266 WO2021121327A1 (en) 2019-12-19 2020-12-17 Substituted straight chain spiro derivatives

Publications (1)

Publication Number Publication Date
CO2022009085A2 true CO2022009085A2 (es) 2022-07-08

Family

ID=76476870

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009085A CO2022009085A2 (es) 2019-12-19 2022-06-29 Derivados espiránicos sustituidos de cadena lineal

Country Status (19)

Country Link
US (1) US20230142285A1 (es)
EP (1) EP4077312A4 (es)
JP (1) JP2023506530A (es)
KR (1) KR20220118500A (es)
CN (1) CN114867721A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
TW (1) TW202138367A (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3214746A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
JP2024518434A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
EP4337216A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
WO2022237719A1 (en) 2021-05-11 2022-11-17 Janssen Pharmaceutica Nv Combination therapies
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
IL309359A (en) * 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer
TW202333690A (zh) * 2021-12-03 2023-09-01 大陸商燁輝醫藥科技（上海）有限公司 羰基取代的二氮雜螺化合物及其用途
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
EP3165530B1 (en) * 2014-07-04 2018-12-05 Qilu Pharmaceutical Co., Ltd Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
EP3394064A1 (en) * 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
KR102493644B1 (ko) * 2016-09-14 2023-01-30 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 스피로 바이사이클릭 억제제
MX2019003091A (es) * 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
WO2018175746A1 (en) * 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
US11542248B2 (en) * 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
WO2020069027A1 (en) * 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin

Also Published As

Publication number Publication date
EP4077312A4 (en) 2024-01-17
CR20220346A (es) 2022-10-26
PE20230162A1 (es) 2023-02-01
JOP20220154A1 (ar) 2023-01-30
KR20220118500A (ko) 2022-08-25
JP2023506530A (ja) 2023-02-16
AU2020404305A1 (en) 2022-08-04
TW202138367A (zh) 2021-10-16
IL293965A (en) 2022-08-01
UY38988A (es) 2021-06-30
MX2022007652A (es) 2022-09-23
EP4077312A1 (en) 2022-10-26
CL2023001530A1 (es) 2023-11-03
CN114867721A (zh) 2022-08-05
ECSP22054700A (es) 2022-11-30
CL2023001531A1 (es) 2023-11-03
DOP2022000125A (es) 2022-08-31
CL2022001583A1 (es) 2023-02-03
US20230142285A1 (en) 2023-05-11
CA3161045A1 (en) 2021-06-24
WO2021121327A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CO2022009085A2 (es) Derivados espiránicos sustituidos de cadena lineal
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
UY35293A (es) Isotiazoles sustituidos con amino
DOP2013000084A (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
ECSP066928A (es) Derivados de carbolina útiles en la inhibición de la angiogénesis
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
ECSP23095641A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
BR112023023154A2 (pt) Derivados espiro substituídos
BR112023021040A2 (pt) Derivados espiro substituídos
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer